Literature DB >> 2524188

Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors.

M R Walker1, J Lund, K M Thompson, R Jefferis.   

Abstract

Aglycosylated human IgG1 and IgG3 monoclonal anti-D (Rh) and human IgG1 and IgG3 chimaeric anti-5-iodo-4-hydroxy-3-nitrophenacetyl (anti-NIP) monoclonal antibodies produced in the presence of tunicamycin have been compared with the native glycosylated proteins with respect to recognition by human Fc gamma RI and/or Fc gamma RII receptors on U937, Daudi or K562 cells. Human red cells sensitized with glycosylated IgG3 form rosettes via Fc gamma RI with 60% of U937 cells. Inhibition of rosette formation required greater than 35-fold concentrated more aglycosylated than glycosylated human monoclonal anti-D (Rh) antibody. Unlabelled polyclonal human IgG and glycosylated monoclonal IgG1 and anti-D (Rh) antibody inhibited the binding of 125I-labelled monomeric human IgG binding by U937 Fc gamma RI at concentrations greater than 50-fold lower than the aglycosylated monoclonal IgG1 anti-D (Rh) (K50 approximately 3 x 10(-9) M and approximately 6 x 10(-7) M respectively). Similar results were obtained using glycosylated and aglycosylated monoclonal human IgG1 or IgG3 chimaeric anti-NIP antibody-sensitized red cells rosetting with Fc gamma RI-/Fc gamma RII+ Daudi and K562 cells. Rosette formation could be inhibited by the glycosylated form (at greater than 10(-6) M) but not by the aglycosylated form. Haemagglutination analysis using a panel of murine monoclonal antibodies specific for epitopes located on C gamma 2, C gamma 3 or C gamma 2/C gamma 3 interface regions did not demonstrate differences in Fc conformation between the glycosylated or aglycosylated human monoclonal antibodies. These data suggest that the Fc gamma RI and Fc gamma RII sites on human IgG are highly conformation-dependent and that the carbohydrate moiety serves to stabilize the Fc structure rather than interacting directly with Fc receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524188      PMCID: PMC1138517          DOI: 10.1042/bj2590347

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  30 in total

1.  Immunogenic and antigenic epitopes of immunoglobulins binding of human monoclonal anti-D antibodies to FcRI on the monocyte-like U937 cell line.

Authors:  M R Walker; B M Kumpel; K Thompson; J M Woof; D R Burton; R Jefferis
Journal:  Vox Sang       Date:  1988       Impact factor: 2.144

Review 2.  Endocytosis.

Authors:  S C Silverstein; R M Steinman; Z A Cohn
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

3.  Recognition of IgG by Fc receptor and complement: effects of glycosidase digestion.

Authors:  N Koide; M Nose; T Muramatsu
Journal:  Biochem Biophys Res Commun       Date:  1977-04-25       Impact factor: 3.575

4.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

5.  Monoclonal antibodies (McAbs) to determinants on human gamma chains: properties of antibodies showing subclass restriction or subclass specificity.

Authors:  J Lowe; P Bird; D Hardie; R Jefferis; N R Ling
Journal:  Immunology       Date:  1982-10       Impact factor: 7.397

6.  Effects of pH treatments and deglycosylation of rabbit immunoglobulin G on the binding of C1q.

Authors:  J L Winkelhake; T J Kunicki; B M Elcombe; R H Aster
Journal:  J Biol Chem       Date:  1980-04-10       Impact factor: 5.157

7.  A common mechanism for the synthesis of membrane and secreted immunoglobulin alpha, gamma and mu chains.

Authors:  W Cushley; B E Coupar; C A Mickelson; A R Williamson
Journal:  Nature       Date:  1982-07-01       Impact factor: 49.962

8.  Responses of human platelets to immunologic stimuli: independent roles for complement and IgG in zymosan activation.

Authors:  S E Martin; R T Breckenridge; S I Rosenfeld; J P Leddy
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

Review 9.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

10.  Prostaglandin synthesis by macrophages requires a specific receptor-ligand interaction.

Authors:  C A Rouzer; W A Scott; J Kempe; Z A Cohn
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

View more
  46 in total

1.  Second Jenner international glycoimmunology meeting.

Authors: 
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

2.  Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Authors:  Shan Chung; Valerie Quarmby; Xiaoying Gao; Yong Ying; Linda Lin; Chae Reed; Chris Fong; Wendy Lau; Zhihua J Qiu; Amy Shen; Martin Vanderlaan; An Song
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 3.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

4.  Functional interactions of aglycosylated monoclonal anti-D with Fc gamma RI+ and Fc gamma RIII+ cells.

Authors:  K A Leader; B M Kumpel; A G Hadley; B A Bradley
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

5.  Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors.

Authors:  Stephen L Sazinsky; René G Ott; Nathaniel W Silver; Bruce Tidor; Jeffrey V Ravetch; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

6.  HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells.

Authors:  Rebecca T Veenhuis; Zachary T Freeman; Jack Korleski; Laura K Cohen; Guido Massaccesi; Alessandra Tomasi; Austin W Boesch; Margaret E Ackerman; Joseph B Margolick; Joel N Blankson; Michael A Chattergoon; Andrea L Cox
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

7.  Serum glycan signatures of gastric cancer.

Authors:  Sureyya Ozcan; Donald A Barkauskas; L Renee Ruhaak; Javier Torres; Cara L Cooke; Hyun Joo An; Serenus Hua; Cynthia C Williams; Lauren M Dimapasoc; Jae Han Kim; Margarita Camorlinga-Ponce; David Rocke; Carlito B Lebrilla; Jay V Solnick
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-10

8.  Optimized expression of full-length IgG1 antibody in a common E. coli strain.

Authors:  Conrad En Zuo Chan; Angeline Pei Chiew Lim; Annie Hoi Yi Chan; Paul A MacAry; Brendon John Hanson
Journal:  PLoS One       Date:  2010-04-20       Impact factor: 3.240

9.  Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.

Authors:  Janet Jackman; Yongmei Chen; Arthur Huang; Barbara Moffat; Justin M Scheer; Steven R Leong; Wyne P Lee; Juan Zhang; Navneet Sharma; Yanmei Lu; Suhasini Iyer; Robert L Shields; Nancy Chiang; Michele C Bauer; Diana Wadley; Merone Roose-Girma; Richard Vandlen; Daniel G Yansura; Yan Wu; Lawren C Wu
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

10.  Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.

Authors:  Akito Natsume; Rinpei Niwa; Mitsuo Satoh
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.